Join for Free!
112430 members
table of contents table of contents

A case-control study of Parkinson's disease (PD) was conducted in the city …

Biology Articles » Genetics » Ecological Genetics » Genetics, drugs and environmental factors in parkinson's disease (A case-control study) » References

- Genetics, drugs and environmental factors in parkinson's disease (A case-control study)

1. Chan P, Tanner CM, Langston JW. Genetically determined differences in xenobiotic metabolism as a risk factor in Parkinson's disease. Fundam Appl Toxicol 1996;30(Suppl):89.

2. Chan P, Tanner CM, Langston JW. A new CYP2D6 mutation associated with Parkinson's disease in American Caucasians. Mov Disord 1995;10:689.

3. Myrianthopoulos NC, Kurland AA, Kurland LT. Hereditary predisposition in drug-induced Parkinsonism. Arch Neurol 1962;6:5-12. 

4. Schwab RS, England AC. Parkinson's syndromes due to various specific causes. In Vinken PJ, Bruyn GH (eds). Handbook of clinical neurology. Armsterdam: North-Holland, 1975:248-266.

5. Calne DB, McGeer E, Eisen A, Spencer P. Alzheimer diosease, Parkinson's disease and motoneurone disease: abiotropic interaction between aging and environment? Lancet 1986;2:1067-1070.

6. Langston JW. Mechanisms underlying neuronal degeneration in Parkinson's disease: an experimental and theoretical treatise. Mov Disord 1989;4(Suppl 1):S15-S25.

7. Davis GC, Williams AC, Markey SP, et al. Chronic parkinsonism secondary to intravenous injection of meperidine-analog synthesis. Psychiat Res 1979;1:249-254.

8. Vingerhoets FJG, Snow BJ, Langston JW, et al. Evolution of subclinical dopaminergic lesions in MPTP-exposed humans. Neurology 1993;43(Suppl2):A389.

9. Nicklas WJ, Vyas I, Heikilla RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpiridine, a metabolite of the neurotoxin 1 - methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci 1985;36:2503-2508.

10. Schapira AHV, Cooper JM, Dexter D, Jenner P, Clack JB, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989;1:1269.

11. Burkhardt C, Kelly JP, Lim Y-H, Filley CM, Parker D. Jr. Neuroleptic medication inhibit complex I of the electron transport chain. Ann Neurol 1993;33:512-517.

12. Veitch K, Hue L. Flunarizine and cinarizine inhibit complexes I and II: possible implications for Parkinsonism. Mol Pharmacol 1994;45:158-163.

13. Christensen E, Moller JE, Faurbye A. Neuropathological investigation of 28 brains from patients with dyskynesia. Acta Psych Scand 1970;46:14-30.

14. Wilson JA, Primrose WR, Smith RG. Prognosis of drug-induced Parkinson's disease. Lancet 1987;1:443-444.

15. Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson's disease. Ann Neurol 1992;32(Suppl):S132-S137.

16. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathologic study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.

17. Koller WC. How accurately can Parkinson's disease be diagnosed? Neurology 1992;42(Suppl 1):6-16.

18. Morens DM, Grandinetti A, Reed D, White LR, Ross GW. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology 1995;45:1041-1045.

19. Reshef A, Rabey JM, Bar P, Schlosberg A, Korczyn AD. Smoking and drug-induced parkinsonism (Abstr). Neurology 1987;37(Suppl 1):121.

20. Duvoisin RC. The genetics of Parkinson's diasease. In Narabayashi H, Nagatsu T, Mizuno Y (eds). Adv Neurol. 1991:306-315. 

21. Calne S, Shoenberg B, Martin W, et al. Familial Parkinson's disease: possible role of environmental factors. Can J Neurol Sci 1987;14:303-305.

22. Martin WE, Young WI, Anderson VE. Parkinson's disease: a genetic study. Brain 1973;96:495-506 

23. Chase TN, Schnur JA, Gordon EK. Cerebrospinal fluid monoamine catabolites in drug-induced extrapyramidal disorders. Neuropharmacology 1970;9:265-275.

24. Barbeau A, Cloutier T, Roy M, Plasse L, Poirier J. Ecogenetics of Parkinson's disease: 4-hydroxilation of debrisoquine. Lancet 1985;2:1213-1216. 

25. Ferraz HB, Bertolucci HF, Pereira JS, Lima JGC, Andrade LAF. Chronic exposure to the fungicide maneb may produce symptoms and signs of manganese intoxication. Neurology 1988;38:550-553.

26. Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tertahydropiridine (MPTP): seven cases. Neurology 1985;35:949-956.

27. Semchuck KM, Love El, Lee RG. Parkinson's disease: a test of the multifactorial etiologic hypothesis. Neurology 1993;43:1173-1180.

28. Tanner CM, Chen B, Wang W, et al. Environmental factors and Parkinson's disease: a case-control in China. Neurology 1989;39:660-664.

29. Ngim CH, Devathanam G. Epidemiologic study on the association between body burden mercury levels and idiopathic Parkinson's disease. Neuroepidemiology 1989;8: 128-141. 

30. Gorell JM, Johnson CC, Rybicki BA, et al. Occupational exposures to metals as risk factors for Parkinson's disease. Neurology 1997;48:650-658. 

31. Tetud JW, Langston JW, Irwin I, Snow B. Parkinsonism caused by petroleum waste ingestion. Neurology 1994;44:1051-1054. 

32. Rajput AH, Rozdilsky B, Hornykiewcz O, Shannack K, Lee T, Seeman P. Reversible drug-induced parkinsonism. Arch Neurol 1982;39:644-646.

33. Bamrah JS, Soni SD. Drug-induced Parkinson's disease. Lancet 1987;1:1031-1032.

34. Melo Souza SE. Flunarizina, parkinsonismo e depressão (Abstr). Goiânia: XI Congresso Brasileiro de Neurologia,1984,p39.

35. Chouza C, Caamaño JZ, De Medina O, Scaramelli A, Aljinati R. Funarizine-induced extrapyramidal syndrome (Abstr). New York:VIII International Symposium on Parkinson's Disease, 1985:96.

36. Subramanyan B, Rollema H, Woolf T, Castagnoli N Jr. Identification of a potential neurotoxic pyridinium metabolite of haloperidol in rats. Bioch Bioph Res Comm 1990;166:238-244.  

37. Haas HH, Chir B, Nasirian F, et al. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann Neurol 1995;37:714-722.

38. De Vries D, Beart PM. Competitive inhibition of (3 H)spirone binding to D-2 dopamine receptors in striatal homogenates by organic calcium channel antagonists and poyvalent cations. Eur J Pharmacol 1984;106:133-139.   

39. Figiel GS, Krishnan RR, Doraiswamy M, Nemeroff CB. Caudate hyperintensities in elderly depressed patients with neuroleptic-induced parkinsonism. J Geriatr Psychiatry Neurol 1991;4:86-89.     

40. Bocola V, Fabbrini G, Sollecito A, Paladini C, Martucci N. Neuroleptic induced parkinsonism: MRI findings in relation to clinical course after withdrawal of neuroleptic drugs. J Neurol Neurosurg Psichiatry 1996;60:213-216.    

41. Ben-Slachar D, Youdim MBH. Neuroleptic induced dopamine receptor supersensivity and tardive dyskinesia may involve altered brain iron metabolism. Br J Pharmacol 1987;90:95.     

42. Guttman M, Burkholder J, Kish SJ et al. [11 C] RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold. Neurology 1997;48:1578-1583.    

rating: 1.00 from 1 votes | updated on: 29 Jun 2009 | views: 2943 |

Rate article: